Key result
Percutaneous coronary intervention combined with PAH-specific medications decreased pulmonary vascular resistance from 9.49 to 3.43 Wood Units, allowing successful atrial septal defect closure.
Why the study?
Left main coronary artery compression is a severe complication in pulmonary arterial hypertension, and optimal treatment strategies require individualization.
Does PCI combined with PAH-specific medications improve hemodynamics and allow ASD closure in a patient with ASD-PAH and left main coronary compression syndrome?
Case Report (n=1)
Does PCI combined with PAH-specific medications improve hemodynamics and allow ASD closure in a patient with ASD-PAH and left main coronary compression syndrome?
A treat-repair-treat strategy using PCI and PAH-specific medications successfully reduced PVR and allowed ASD closure in a patient with ASD-PAH and left main coronary compression syndrome.
May support treat-repair-treat in select ASD-PAH with coronary compression; leaves open generalizability beyond this case.
Compression of left main coronary artery is a severe complication in PAH and the treatment strategy is tricky and should be individualized. We presented a patient with large atrial septal defect (ASD) and non-Eisenmenger pulmonary arterial hypertension (PAH). Right heart catheterization (RHC) showed the defect was non-correctable due to a pulmonary vascular resistance (PVR) of 9.49 Wood Units. EKG suggested myocardial ischemia and coronary angiography and coronary CTA confirmed proximal left main coronary artery was compressed by extremely dilated pulmonary arterial trunk, which is named left main coronary compression syndrome (LMCS). Percutaneous coronary intervention (PCI) using drug-eluting stent was performed and combined PAH-specific medications was prescribed simultaneously. At 6-month following the PCI procedure, PVR had decreased to 3.43 Wood Units, and percutaneous ASD closure procedure was performed. A 6-month follow-up the patient was asymptomatic and had significantly improved pulmonary hemodynamics. LMCS is rare among patients with ASD-PAH. PCI combined with PAH-specific medications allowed the closure of ASD, resulting in clinical improvement.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) conducted a case report in Pulmonary arterial hypertension associated with atrial septal defect and left main coronary compression syndrome (n=1). Percutaneous coronary intervention (PCI) combined with PAH-specific medications and subsequent ASD closure was evaluated on Pulmonary vascular resistance (PVR) and clinical symptoms. Percutaneous coronary intervention combined with PAH-specific medications decreased pulmonary vascular resistance from 9.49 to 3.43 Wood Units, allowing successful atrial septal defect closure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: